Fund+ Makes Moves In Europe With Further Growth On The Cards
VC Playbook: Exploring Fund+
Executive Summary
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.
You may also be interested in...
ExeVir Bio Looks To Llamas To Tackle Coronavirus Crisis
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
Spanish Oncology Start-Up Ona Raises €30m
A syndicate of high-profile investors are backing the Barcelona-based firm's bid to develop biologics targeting metastatic-initiating cells and lipid metabolism.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.